Compare Amphastar Pharmaceuticals Inc (AMPH) vs MasTec Inc (MTZ) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

MasTec (MTZ) trades at $372.89, down 3.07% on the day, with a neutral technical signal and strong fundamental backdrop. The stock shows robust earnings momentum, beating estimates for three consecutive quarters, and benefits from a record $20.3 billion backlog. Recent acquisition of The Superior Group for $1.65 billion enhances its data center infrastructure capabilities, positioning the company for growth in AI-driven power demand and broadband expansion.

Outlook remains positive with 88.9% analyst buy ratings and a $479.85 consensus price target implying 28.7% upside. Key risks include execution of large acquisitions and integration challenges, while high P/E of 65.3 suggests premium valuation. Revenue growth and margin expansion from infrastructure spending trends support long-term potential, but investors should monitor debt levels and competitive pressures.